Physician profile
Michael Mclaughlin
NPI 1376779231
$6,877.35
in general payments reported to CMS, 2019-2025
20 companies · $890 in 2025
The $890 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,890 · 2020: $993 · 2021: $794 · 2022: $615 · 2023: $365 · 2024: $331 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180 · Travel and Lodging: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.37 |
| Travel and Lodging | $405.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,431.46 | 2019-2025 | Proclaim, Eterna, Ionicrf |
| Medtronic USA, INC. | $2,321.65 | 2019-2020 | |
| Boston Scientific Corporation | $485.42 | 2019-2025 | General - Therapies, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $112.91 | 2021-2023 | Kyphon Express II Kyphopak Tray |
| Biohaven Pharmaceutical Holding Company Ltd. | $75.08 | 2022 | |
| Spr Therapeutics, INC | $51.67 | 2025 | Sprint Pns System |
| Pfizer INC. | $49.69 | 2019-2020 | |
| Novo Nordisk INC | $47.90 | 2022-2023 | Rybelsus, Ozempic |
| Amgen INC. | $47.73 | 2019-2020 | |
| Dexcom, INC. | $47.61 | 2023 | Dexcom G6 Transmitter |
| Nevro Corp. | $43.19 | 2019 | |
| Idorsia Pharmaceuticals US INC | $30.26 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $24.67 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.54 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $16.77 | 2025 | |
| Arbor Pharmaceuticals, INC. | $14.93 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.66 | 2025 | Horizant |
| Astrazeneca Pharmaceuticals Lp | $13.04 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.